Azerbaijani
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Long-Term Study of Nitisinone to Treat Alkaptonuria

Yalnız qeydiyyatdan keçmiş istifadəçilər məqalələri tərcümə edə bilərlər
Giriş / Qeydiyyatdan keçin
Bağlantı panoya saxlanılır
StatusTamamlandı
Sponsorlar
National Human Genome Research Institute (NHGRI)

Açar sözlər

Mücərrəd

This 3-year study will examine the safety and effectiveness of long-term use of nitisinone (Orfadin) for treating joint problems in patients with alkaptonuria, an inherited disease in which a compound called homogentisic acid accumulates. The excess homogentisic acid causes arthritis and limited joint movement. It can also cause heart valve damage and kidney stones.
Patients between 30 and 80 years of age with alkaptonuria may be eligible for this study. Patients must have hip involvement, but at least one remaining hip joint. Candidates are recruited from among patients enrolled in protocol 00-HG-0141, "Clinical, Biochemical, and Molecular Investigations into Alkaptonuria." Participants may enter both protocols simultaneously.
Participants are randomly assigned to one of two treatment groups: one group takes their regular medicines plus a 2-mg nitisinone capsule daily; the other group takes only their regular medicines. Patients taking nitisinone have blood tests to measure liver function 2 weeks and 6 weeks after starting treatment. Before starting therapy, all patients are admitted to the NIH Clinical Center for 4-5 days to undergo the following procedures:
- Medical history and physical examination
- 24-hour urine collection to test for sugar, protein, and other molecules
- Blood tests for liver and thyroid function, blood counts, and blood chemistries
- Blood and urine tests to measure tyrosine and other amino acids and homogentisic acid
- Bone x-rays
- Spiral CT (computed tomography) of the abdomen to detect kidney stones
- Eye examination and evaluations by specialists in rehabilitation medicine and pain, plus other consults in skin, brain, lung, heart, and kidney, as needed
All patients, whether or not they receive nitisinone, return to the Clinical Center for a 2-3 day follow-up admission every 4 months for a history and physical examination, blood tests, and two 24-hour urine collections. Every 12 months (12, 24 and 36 months after starting the study), patients also have repeat bone x-rays, spiral CT, kidney ultrasound, echocardiogram, and electrocardiogram. An MRI of the brain is done at the end of the study.
Sixteen months after the end of the study enrollment period, the treated and non-treated groups are evaluated. If nitisinone has delayed the progression of joint disease in the treated group, the study continues and all patients receive the drug for the remainder of the study. If not, the study continues for another 20 months, at which time the study ends and the evaluation process is repeated.
Patients who develop symptoms such as corneal crystals, pain, or severe liver or nervous system toxicity may be taken off the study.

Təsvir

Alkaptonuria is a rare metabolic disease in which homogentisic acid (HGA), an intermediary metabolite in tyrosine catabolism, accumulates due to deficiency of the enzyme homogentisic acid oxidase. Patients with alkaptonuria exhibit homogentisic aciduria and ochronosis, or dark pigmentation of various tissues due to binding of HGA and its oxidized metabolites. The ochronosis results in debilitating destruction of cartilage, arthritis, lumbosacral ankylosis, limitation of motion, and bone deterioration in later life. No effective therapy exists for alkaptonuria. However, a compound named 2-(2-nitro-4-trifluoromethylbenzoyl) - 1, 3-cyclohexanedione (nitisinone, NTBC, Orfadin) inhibits 4-hydroxyphenylpyruvate dioxygenase, the enzyme that produces HGA. Nitisinone, at doses of approximately 1 mg/kg/day, has proven safe and effective in tyrosinemia type I, which causes fatal liver disease in infants and children. Under protocol 97-HG-0201, we treated 9 alkaptonuria patients with nitisinone; for the 7 who received 1.05 mg twice daily, the HA fell from 4.0 plus or minus 1.8 g/24h to 0.2 plus or minus 0.2 g/24h (normal 0.028 plus or minus 0.015 g/24h, n=10). Plasma tyrosine levels rose from 67 plus or minus 18 micro M to 760 plus or minus 181 micro M. The current protocol (05-HG-0076) is a randomized, controlled clinical trial to determine if nitisinone (2 mg daily) is beneficial for the joint symptoms of alkaptonuira. Patients are examined at the NIH Clinical Research Center every 4 months for 3 years. Hip joint range of motion serves as the primary outcome parameter, and nitisinone (Orfadin) is provided by Swedish Orphan International through an IND obtained by William A. Gahl. Forty patients (20 with nitisinone treatment and 20 untreated) have been enrolled for at least 16 months, and an interim analysis shows promising results. Serious adverse events in patients on nitisinone have included a death from myocardial infarction, keratopathy, and elevated liver function tests related to gallstones.

Tarixlər

Son Doğrulandı: 11/30/2010
İlk təqdim: 04/06/2005
Təxmini qeydiyyat təqdim edildi: 04/06/2005
İlk Göndərmə: 04/07/2005
Son Yeniləmə Göndərildi: 12/19/2010
Son Yeniləmə Göndərildi: 01/18/2011
İlk təqdim edilmiş nəticələrin tarixi: 12/19/2010
İlk təqdim edilmiş QC nəticələrinin tarixi: 12/19/2010
İlk göndərilən nəticələrin tarixi: 01/18/2011
Həqiqi Təhsilin Başlama Tarixi: 12/31/2004
Təxmini İlkin Tamamlanma Tarixi: 03/31/2009
Təxmini İşin Tamamlanma Tarixi: 03/31/2009

Vəziyyət və ya xəstəlik

Alkaptonuria

Müdaxilə / müalicə

Drug: Nitisinone-treated

Faza

Faza 2

Qol Qrupları

QolMüdaxilə / müalicə
No Intervention: Control
No treatment
Experimental: Nitisinone-treated
Subjects received nitisinone 2 mg orally, once daily.
Drug: Nitisinone-treated
Treatment

Uyğunluq Kriteriyaları

Təhsil üçün uyğun yaşlar 30 Years Üçün 30 Years
Təhsilə Uyğun CinslərAll
Sağlam Könüllüləri qəbul edirBəli
Kriteriyalar

- INCLUSION CRITERIA:

- Age 30-80 years, either gender

- Diagnosis of alkaptonuria based upon urinary HGA excretion greater than 0.4 g/24h

- At least one hip joint remaining

- Some evidence of hip involvement, e.g., pain or decreased range of motion

- Ability to travel to the NIH Clinical Research Center for admissions

- Ability to consent

- Availability of local medical follow-up

EXCLUSION CRITERIA:

- Age less than 30 or greater than 80

- Non-alkaptonuria causes of ochronosis

- Bilateral hip joint replacement

- Keratopathy

- Contact lenses

- Uncontrolled glaucoma

- History of myocardial infarction

- History of emphysema or pulmonary insufficiency (Forced vital capacity less than 70%)

- Psychiatric illness or neurological disease that interferes with compliance or communication with health care personnel

- Current malignancy

- Open skin lesions

- Dietary habits or use of homeopathic therapies that interfere with tyrosine catabolism. The diet must be reasonably balanced, as determined by a dietician.

- Uncontrolled hypertension (blood pressure greater than 180 systolic or greater than 95 diastolic)

- History of extreme alcohol abuse or sever liver disease

- Liver greater than 3 cm below the right costal margin

- Electrocardiogram changes indicative of myocardial infarction, arrhythmia, tachycardia, bradycardia, left bundle branch block

- Chest radiographic abnormalities, including an infiltrate, mass, congestive heart failure, embolism, atelectasis

- Serum postassium less than 3. 0 mEq/L

- Serum creatinine greater than 2.0 mg/dL

- SGPT greater than 41 U/L or SGOT greater than 34 U/L

- CK greater than 500 U/L

- Hemoglobin less than 10.0 g/dL

- Platelets less than 100 k/mm(3)

- WBC less than 3.0 k/microL

- T4 greater than 15 microg/dL

- T4 less than 4 microg/dL

- ESR greater than 100 mm/h

- Plasma tyrosine greater than 150 microM

Nəticə

İlkin nəticə tədbirləri

1. Change in Total ROM Worse Hip. [Measured at baseline and at 36 months]

Change from baseline in the total (external + internal) hip range of motion (ROM) in the worse hip at 36 months.

İkincili Nəticə Tədbirləri

1. Change in Schober's Test [Measured at baseline and at 36 months]

Change from baseline of Schober's test at 36 months. Schober's test measures a patient's ability to flex his/her lower back. The examiner makes a mark at L5 (fifth lumbar vertebra) and places one finger 5 cm below and another finger 10 cm above this mark. The patient is asked to touch his/her toes. The examiner measures the increase in distance between the two fingers.

2. Change in Functional Reach Assessment [Measured at baseline and at 36 months]

Change from baseline of functional reach assessment at 36 months. Functional reach assessment measures the difference between the length of a person's outstretched arm and their maximal reach forward, while maintaining balance.

3. Change in Timed Get up and go [Measured at baseline and at 36 months]

Change from baseline of timed get up and go at 36 months. In timed get up and go, the patient is asked to stand up from a standard chair and walk a distance of 3 meters, turn around and walk back to the chair and sit down. The examiner measures the time it takes for the patient to perform this series of tasks.

4. Change in 6 Minute Walk Test (6MWT) [Measured at baseline and at 36 months]

Change from baseline of the 6MWT at 36 months. The 6MWT measures the distance that a patient can quickly walk on a flat hard surface in a period of six minutes.

Facebook səhifəmizə qoşulun

Elm tərəfindən dəstəklənən ən tam dərman bitkiləri bazası

  • 55 dildə işləyir
  • Elm tərəfindən dəstəklənən bitki mənşəli müalicələr
  • Təsvirə görə otların tanınması
  • İnteraktiv GPS xəritəsi - yerdəki otları etiketləyin (tezliklə)
  • Axtarışınızla əlaqəli elmi nəşrləri oxuyun
  • Təsirlərinə görə dərman bitkilərini axtarın
  • Maraqlarınızı təşkil edin və xəbər araşdırmaları, klinik sınaqlar və patentlər barədə məlumatlı olun

Bir simptom və ya bir xəstəlik yazın və kömək edə biləcək otlar haqqında oxuyun, bir ot yazın və istifadə olunan xəstəliklərə və simptomlara baxın.
* Bütün məlumatlar dərc olunmuş elmi araşdırmalara əsaslanır

Google Play badgeApp Store badge